Lacosamide
- Generic Name
- Lacosamide
- Brand Names
- Motpoly, Vimpat, Lacosamide Adroiq, Lacosamide Accord, Lacosamide UCB
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18N2O3
- CAS Number
- 175481-36-4
- Unique Ingredient Identifier
- 563KS2PQY5
- Background
Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focu...
- Indication
Lacosamide is indicated for the treatment of partial-onset seizures in patients aged one month and older and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients aged four years and older.
- Associated Conditions
- Epilepsy, Primary Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Status Epilepticus
- Associated Therapies
- -
The Safety of Intravenous Lacosamide
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Le Bonheur Children's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT00832884
- Locations
- 🇺🇸
LeBonheur Children's Medical Center, Memphis, Tennessee, United States
Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 1005
- Registration Number
- NCT00771927
Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT00655486
Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT00655551
To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
- First Posted Date
- 2007-11-01
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 370
- Registration Number
- NCT00552305
Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.
- First Posted Date
- 2007-10-18
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 621
- Registration Number
- NCT00546351
- Locations
- 🇧🇪
004, Roeselare, Belgium
🇧🇪002, Genk, Belgium
🇧🇪005, Merksem, Belgium
Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 322
- Registration Number
- NCT00530855
- Locations
- 🇺🇸
137, Waldorf, Maryland, United States
🇺🇸094, Doral, Florida, United States
🇺🇸029, Scarborough, Maine, United States
Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
- First Posted Date
- 2007-08-29
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 308
- Registration Number
- NCT00522275
Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2018-07-19
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 426
- Registration Number
- NCT00520741
- Locations
- 🇺🇸
61, Columbus, Ohio, United States
🇺🇸32, Philadelphia, Pennsylvania, United States
🇺🇸79, Atlanta, Georgia, United States
Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures
- First Posted Date
- 2007-08-14
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 376
- Registration Number
- NCT00515619
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.